JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 45:185-197, doi:10.1016/j.jacc.2004.10.031
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (76)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birjmohun, R. S.
Right arrow Articles by Stroes, E. S.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birjmohun, R. S.
Right arrow Articles by Stroes, E. S.G.

STATE-OF-THE-ART PAPERS

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

A meta-analysis of randomized controlled trials

Rakesh S. Birjmohun, MD*,*, Barbara A. Hutten, PhD{dagger}, John J.P. Kastelein, MD, PhD* and Erik S.G. Stroes, MD, PhD*

* Department of Vascular Medicine
{dagger} Department of Clinical Epidemiology and Biostatistics, Academic Medical Center of Amsterdam, Amsterdam, the Netherlands

Manuscript received May 10, 2004; accepted October 4, 2004.

* Reprint requests and correspondence: Dr. Rakesh S. Birjmohun, Academic Medical Center of Amsterdam, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands (Email: r.s.birjmohun{at}amc.uva.nl).

OBJECTIVES: The aim of this research was to estimate the efficacy and safety of current high-density lipoprotein cholesterol (HDL-C)-increasing drugs.

BACKGROUND: Epidemiologic evidence has shown that HDL-C is inversely related to coronary heart disease (CHD) risk. However, the evidence for reducing CHD risk by raising HDL-C is thin, predominantly due to the paucity of effective and safe HDL-increasing drugs.

METHODS: Randomized controlled trials with fibrates and niacin, published between 1966 through February 2004 (MEDLINE), were retrieved. Information on treatment, baseline characteristics, serum lipids, end points, and side-effects were independently abstracted by two authors using a standardized protocol.

RESULTS: Data from 53 trials (16,802 subjects) using fibrates and 30 trials (4,749 subjects) using niacin were included. Random-effects model showed 11% versus 10% reduction in total cholesterol, 36% versus 20% reduction in triglycerides, 8% versus 14% reduction in low-density lipoprotein cholesterol, and 10% versus 16% increase in HDL-C for fibrates and niacin, respectively. Apart from flushes in the niacin group, both fibrates and niacin were shown to be well-tolerated and safe. Fibrates reduced the risk for major coronary events by 25% (95% confidence interval 10% to 38%), whereas current available data for niacin indicate a 27% reduction.

CONCLUSIONS: Fibrates reduce major coronary events and increase HDL-C levels without significant toxicity. Niacin has a more potent effect on HDL-C levels, whereas data on cardiovascular event rate reduction are limited. Future studies need to evaluate whether additional HDL increase by fibrates or particularly newer niacin formulations on top of statin therapy translates into further event reduction in high-risk subjects, without significant toxicity.

Abbreviations and Acronyms
  CHD = coronary heart disease
  CV = cardiovascular
  ER = extended-release
  HDL-C = high-density lipoprotein cholesterol
  HHS = Helsinki Heart study
  IR = immediate-release
  LDL-C = low-density lipoprotein cholesterol
  SD = standard deviation
  SR = wax-matrix sustained-release
  TC = total cholesterol
  TG = triglycerides
  VA-HIT = Veterans Affairs High-density lipoprotein Intervention Trial




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
N. J. Hime, A. S. Black, J. J. Bulgrien, and L. K. Curtiss
Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP
J. Lipid Res., October 1, 2008; 49(10): 2113 - 2123.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. A. van der Steeg, I. Holme, S. M. Boekholdt, M. L. Larsen, C. Lindahl, E. S.G. Stroes, M. J. Tikkanen, N. J. Wareham, O. Faergeman, A. G. Olsson, et al.
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
J. Am. Coll. Cardiol., February 12, 2008; 51(6): 634 - 642.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. D. Brunzell
Hypertriglyceridemia
N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017.
[Full Text] [PDF]


Home page
LupusHome page
S. Ardoin, C. Sandborg, and L. Schanberg
Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus
Lupus, August 1, 2007; 16(8): 618 - 626.
[Abstract] [PDF]


Home page
J. Lipid Res.Home page
C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. Kodama, S. Tanaka, K. Saito, M. Shu, Y. Sone, F. Onitake, E. Suzuki, H. Shimano, S. Yamamoto, K. Kondo, et al.
Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol: A Meta-analysis
Arch Intern Med, May 28, 2007; 167(10): 999 - 1008.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
W S A Smellie, J Forth, S R S Smart, M J Galloway, W Irving, D Bareford, P O Collinson, K G Kerr, G Summerfield, P J Carey, et al.
Best practice in primary care pathology: review 7
J. Clin. Pathol., May 1, 2007; 60(5): 458 - 465.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
C. Reasner
Rational therapy of mixed dyslipidaemia in a patient with diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 25 - 30.
[Abstract] [PDF]


Home page
Eur Heart JHome page
P. K. Shah
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Eur. Heart J., January 1, 2007; 28(1): 5 - 12.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
C. D. Rochester and C. E. Cooke
The Changing Face of Dyslipidemia Therapies
Journal of Pharmacy Practice, April 1, 2006; 19(2): 79 - 93.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. C.N. Rensen and L. M. Havekes
Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport?
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 681 - 684.
[Full Text] [PDF]


Home page
DOC NewsHome page
K. Ullman
HDL Becoming Important Piece of CHD Puzzle
DOC News, February 1, 2006; 3(2): 9 - 9.
[Full Text]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
M J. Chapman
Review: Fibrates: therapeutic review
The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19.
[Abstract] [PDF]


Home page
HeartHome page
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart, December 1, 2005; 91(suppl_5): v1 - v52.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
E. Bruckert
Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets
Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L16 - L20.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. M. Gotto Jr
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1219 - 1224.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., August 1, 2005; 10(4): 127 - 128.
[Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
P. Barter
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2_suppl): S1 - S15.
[Abstract] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.